Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $120
Buy Rating on Viking Therapeutics: A Strategic Opportunity Amid Market Overreaction
Buy Rating on Viking Therapeutics: Promising VK2735 Development and Strategic Advancements
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Vericel (VCEL)
Truist Financial Keeps Their Buy Rating on Viking Therapeutics (VKTX)
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $105 to $138
Buy Rating Affirmed on Viking Therapeutics as Key Drug Advances to Phase 3 Trials
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $90 to $138
Viking Therapeutics Price Target Maintained With a $90.00/Share by HC Wainwright & Co.
Viking Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Day One Biopharmaceuticals (DAWN)
Truist Financial Releases a Buy Rating on Viking Therapeutics (VKTX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS) and Viking Therapeutics (VKTX)
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Natera (NTRA) and Argenx Se (ARGX)
Stifel Nicolaus Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
Viking Therapeutics Analyst Ratings